Kineta Presents Preclinical Data on New CD27 Program at AACR Tumor Immunology and Immunotherapy Conference | Antibody
Kineta Presents Preclinical Data on New CD27 Program at AACR Tumor Immunology and Immunotherapy Conference
Posted on Saturday, October 09, 2021 10:41
Kineta Expands Company’s Immuno-Oncology Pipeline with Addition of New Monoclonal Antibody Program Targeting CD27
SEATTLE, WA, USA I October 7, 2021 I Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, today announced the presentation of preclinical data on the company’s new immuno-oncology program targeting CD27 at the conference of the American Association for Cancer Research on Tumor Immunology and Immunotherapy. Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta, presented a poster detailing new preclinical data on the company’s main anti-CD27 agonist antibodies.
CD27 is a member of the TNF receptor superfamily and plays an essential role in T cell activation by providing a co-stimulatory signal with its CD70 ligand. CD27 is highly expressed on naive T cells and also provides a co-stimulatory signal for activation of NK cells. A major challenge in cancer immunotherapy is “depletion” of T cells. Cancer T cells, with repeated stimulation, begin to lose their cancer-fighting effector functions. Once a T cell is depleted, any additional stimulation becomes ineffective. CD27 agonist immunotherapy can reprogram the immune system to generate new, more diverse populations of “memory” anti-cancer T cells from naive T cells to elicit a strong anti-tumor response.
“This is an important milestone for Kineta as we expand our pipeline with another exciting immuno-oncology antibody program,” said Shawn Iadonato, PhD, CEO of Kineta. “Our immuno-oncology strategy is to develop differentiated immunotherapies to address key mechanisms of cancer resistance, including immunosuppression, T cell depletion, and lack of tumor antigens. CD27 is a target for cancer. Immunotherapy shows promise to treat depleted T cells and restore anti-tumor T cell function. ”
The main outcomes of the AACR poster presentation are as follows:
- 147 fully human anti-CD27 monoclonal antibodies with unique sequences were generated
- Kineta’s anti-CD27 antibodies are highly specific and cross-react with cyno-CD27
- The anti-CD27 agonist assay showed particularly strong induction for eight of the anti-CD27 antibodies
- Human peripheral blood T cell activation test showed increased cytokine proliferation and secretion
“We are encouraged by the results of our anti-CD27 antibodies, as they performed extremely well in multiple preclinical experiments,” said Thierry Guillaudeux, PhD, SVP Immuno-oncology at Kineta. “We are currently in the process of being selected and will nominate a clinical candidate to move on to studies allowing IND in 2022.”
Title: A promising target for cancer immunotherapy: new fully human agonist antibodies directed against the CD27 costimulatory receptor of human T lymphocytes
Date of presentation: October 5-6, 2021
Presenter: Thierry Guillaudeux, PhD
Attach: Click on the link below to see the poster:
Kineta is a clinical-stage biotechnology company whose mission is to develop next-generation immunotherapies that transform patients’ lives. We have leveraged our expertise in innate immunity to develop world-class or best-in-class immunotherapies that address the main challenges of current cancer therapies. For more information about Kineta, visit our website, www.kinetabio.com, and follow us on Twitter, LinkedIn and Facebook.
THE SOURCE: Kineta